For strategies targeting glycolytic metabolism, we believe two aspects need to be considered: one is to enhance the effects of anti-PD-L1/PD-1 therapy by altering the glucose metabolism of non-tumor cells such as immune cells and tumor vascular endothelial cells; the other is to directly act on the glycolytic process of tumor cells to improve the efficacy of PD-L1/PD-1 therapy. This evidence concerns the gene CD274 and neoplasm.